XML 21 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]      
Revenues $ 3,114.3 $ 2,743.3 $ 2,539.3
Operating expenses:      
Salaries and benefits 907.5 793.8 746.4
Supplies 812.9 745.0 709.7
Professional and medical fees 357.1 296.8 269.2
Lease expense 89.5 84.9 82.4
Other operating expenses 201.7 175.3 156.7
Cost of revenues 2,368.7 2,095.8 1,964.4
General and administrative expenses 138.7 120.9 102.2
Depreciation and amortization 152.6 118.1 114.8
Transaction and integration costs 100.1 61.7 47.5
Net loss on disposals, consolidations and deconsolidations 40.6 14.4 11.1
Equity in earnings of unconsolidated affiliates (19.5) (14.2) (12.5)
Litigation settlements (0.8) 10.6 (29.3)
Loss on debt extinguishment 5.1 15.5 14.9
Other income, net (20.0) (7.5) (19.0)
Total operating expenses 2,765.5 2,415.3 2,194.1
Operating income 348.8 328.0 345.2
Interest expense, net (201.7) (193.0) (234.9)
Income before income taxes 147.1 135.0 110.3
Income tax (expense) benefit (134.6) 0.3 (23.3)
Net income 12.5 135.3 87.0
Less: Net income attributable to non-controlling interests (180.6) (147.2) (141.6)
Net loss attributable to Surgery Partners, Inc. $ (168.1) $ (11.9) $ (54.6)
Net loss per share attributable to common stockholders:      
Basic (in USD per share) $ (1.33) $ (0.09) $ (0.59)
Diluted (in USD per share) [1] $ (1.33) $ (0.09) $ (0.59)
Weighted average common shares outstanding:      
Basic (shares) 126,122 125,613 91,952
Diluted (shares) [1] 126,122 125,613 91,952
[1] The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive.